Group 1 - Quantum BioPharma Ltd. has closed the final tranche of its offering, raising a total of $5 million to advance research and development of innovative drug candidates and for general working capital purposes [1][2] - The company has developed a formulation for rekvry™, aimed at treating alcohol misuse in emergency and hospital settings, addressing an unmet need in healthcare [2] - Quantum BioPharma is focused on neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, showing promise in preventing and reversing myelin degradation in preclinical models [3] Group 2 - The company retains a 25.71% ownership stake in Celly Nutrition, which markets the product UNBUZZD™, and is entitled to a 7% royalty on sales until reaching $250 million, after which the royalty will drop to 3% [3] - Quantum BioPharma maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [3]
Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms